These include the upregulation of ligands of the inhibitory receptors KIR2DL3 and CD244 by myeloma cells, namely FAM3C62, which is also a prominent part of the pancreatic cancer secretome63 and CD4832. This evidence concerns the gene CD244 and plasma cell myeloma.